The American Society of Regional Anesthesia and Pain Medicine (ASRA) periodically updates its practice advisories and associated cognitive aids. The 2020 version of the ASRA Local Anesthetic Systemic Toxicity checklist was created in response to user feedback, simulation studies and advances in medical knowledge. This report presents the 2020 version and discusses the rationale for its update.
- drug-related side effects and adverse reactions
- regional anesthesia
Statistics from Altmetric.com
The American Society of Regional Anesthesia and Pain Medicine (ASRA) periodically updates its practice advisory on Local Anesthetic Systemic Toxicity (LAST)1 2 to incorporate knowledge advancement, feedback sourced from users3 and simulation.4 5 Coincident with these ongoing advances, ASRA LAST management checklists1 6 7 and ASRA LAST smartphone applications are often revised. Herein, we present the 2020 version of the ASRA LAST checklist (figure 1) and discuss the rationale for its redesign.
Design of the 2020 checklist was strongly impacted by a simulation study that identified latent design deficiencies in the 2017 version.8 Similarly, the original 2010 LAST checklist was modified in 20126 based on a simulation study5 that assessed its effectiveness and readability, and it then underwent further modification embodied in the 2017 practice advisory.2 The 2017 update involved experts in checklist design7 and specifically intended to address ambiguities3 and misunderstandings related to lipid emulsion dosing, resuscitation drug selection and timely notification of cardiopulmonary bypass teams. However, a simulation study published in Regional Anesthesia and Pain Medicine compared the 2017 LAST checklist with the 2012 version that it replaced and found no difference in effectiveness or readability.4
The 2020 checklist’s most important modification was conversion of the traditional bullet-pointed design to a process-flow format similar to the ASRA LAST smartphone application.9 This change responds to some simulation participants who found portions of both the 2012 and 2017 checklists difficult to follow and wordy. For instance, the 2012 checklist prescribes airway management during seizure as ‘ventilate with 100% oxygen’ while the 2017 checklist task prescribes ‘ventilate with 100% oxygen/avoid hyperventilation/advanced airway device if necessary’. Indeed, subjects that were randomized to the less wordy 2012 checklist performed slightly better on LAST management tasks (a secondary outcome, effect size 1.01),4 which in part supports using a more concise format. Therefore, instead of using a sequential list of management steps, we aim to improve critical incident management with a process-flow format that identifies individual decision points such as seizure management (standard diamond shape) and links treatment to specific actions (process rectangles).10
Simulation and user feedback also highlighted an important and ongoing management deficit—failure to recognize that LAST resuscitation differs from Advanced Cardiac Life Support (ACLS)-guided resuscitation (animal studies show that many standard ACLS drugs worsen LAST outcomes).11 When some simulation subjects chose to use both LAST and ACLS checklists, the resulting confusion and missteps led to delayed and errant treatment.4 Admonitions placed near the top of previous checklists did not eliminate this defect, thus the 2020 redesign incorporates a standard triangular caution symbol to emphasize therapeutic differences. We further simplified lipid emulsion dosing instructions in response to reported difficulties calculating weight-based dosing and timing of lipid administration,3 which reflect practitioner preference for a level of precision that is unnecessary and unsupported by experimental studies.
In summary, the 2020 version of the ASRA LAST checklist was created in response to advances in medical knowledge, user feedback and simulation. We hope that a process-flow format achieves a more concise and logical cognitive aid.
Contributors JMN contributed to checklist content and prepared and approved the manuscript. EJN rendered graphic design and approved the manuscript. GLW contributed to checklist content and prepared and approved the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests JMN and GLW served on the 2010 and 2017 American Society of Regional Anesthesia and Pain Medicine (ASRA). Local Anesthetic Systemic Toxicity practice advisory panels. GLW is an officer and shareholder of ResQ Pharma. EJN was compensated for graphic design.
ASRA approved the 2020 version of this checklist, but had no input into its scientific content.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement There are no data in this work.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.